AI Article Synopsis

  • Endoscopic submucosal dissection (ESD) is a safe and minimally invasive treatment for early gastric and esophageal tumors, but postoperative epigastric pain is a common issue that can be more severe than previously thought, affecting up to 62.8% of patients.
  • This study aims to evaluate the effectiveness of using dexmedetomidine (DEX) for managing postoperative pain in ESD patients by comparing pain levels recorded on a visual analog scale (VAS) within 48 hours after surgery.
  • A randomized control trial involving 120 patients will compare the DEX group's pain and other outcomes against a control group receiving normal saline, monitoring various factors like pain intensity, blood pressure, and postoperative complications.

Article Abstract

Background: Endoscopic submucosal dissection (ESD) is widely used as an effective treatment of early gastric and esophageal tumors, as it is minimally invasive, safe, and convenient. Epigastric pain is a common complication of ESD. In the traditional cognition, the postoperative pain of ESD is not serious and does not attach too much attention. However, previous studies found that the incidence of moderate to severe pain after ESD can be as high as 44.9~62.8%. At present, there is no unified understanding of how to carry out good postoperative analgesia in patients undergoing ESD of stomach and esophagus. The purpose of present study is to investigate the efficacy of intraoperative dexmedetomidine (DEX) using on postoperative pain though observing the postoperative visual analog scale (VAS) score within 48 h after ESD surgery, so as to explore an effective analgesia and anesthetic method in patients undergoing gastric and esophagus ESD.

Methods/design: This study is a prospective, single-center, two-arm, randomized control trail. In total, 120 patients undergoing endoscopic submucosal dissection were stratified by type of surgery (i.e., gastric or esophagus ESD) and randomized into two treatment groups, DEX group (group D, n = 60) and control group (group C, n = 60). Patients in the experimental group (DEX group) will be administrated a loading dose of DEX at 1 μg/kg for 15 min and a continuous infusion at 0.6 μg/kg/h until 30 min before the end of operation. In control group, the same volume of normal saline was infused. The primary outcome is VAS at 2 h after ESD surgery. The secondary outcome will be VAS at 1 h, 4 h, 6 h,18 h, 24 h, and 48 h, the status of perioperative hemodynamics, the use of remedial analgesics, sedation score, shivering, postoperative nausea and vomiting (PONV), and satisfaction scores of patient and complication of ESD (such as bleeding, perforation, aspiration pneumonia).

Discussion: The results of this study will demonstrate that intraoperative application of DEX is beneficial for postoperative pain treatment in patients undergoing ESD. This study will not only confirm that postoperative pain treatment is necessary for patients undergoing ESD but also provides an effective anesthesia method for postoperative analgesia.

Trial Registration: Chinese Clinical Trial Registry, ID: ChiCTR2100043837 , registered on March 4, 2021, http://www.chictr.org.cn .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195240PMC
http://dx.doi.org/10.1186/s13063-022-06432-4DOI Listing

Publication Analysis

Top Keywords

patients undergoing
24
postoperative pain
20
endoscopic submucosal
12
submucosal dissection
12
undergoing esd
12
esd
11
postoperative
9
undergoing gastric
8
gastric esophageal
8
esd effective
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!